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Abstract: BACKGROUND: Gliomas evade current therapies through primary and acquired resistance
and the effect of temozolomide is mainly restricted to methylguanin-O6-methyltransferase promoter
(MGMT) promoter hypermethylated tumors. Further resistance markers are largely unknown and would
help for better stratification. METHODS: Clinical data and methylation profiles from the NOA-08 (104,
elderly glioblastoma) and the EORTC 26101 (297, glioblastoma) studies and 398 patients with glioblas-
toma from the Heidelberg Neuro-Oncology center have been analyzed focused on the predictive effect of
DNA damage response (DDR) gene methylation. Candidate genes were validated in vitro. RESULTS:
Twenty-eight glioblastoma 5’-cytosine-phosphat-guanine-3’ (CpGs) from 17 DDR genes negatively cor-
related with expression and were used together with telomerase reverse transcriptase (TERT) promoter
mutations in further analysis. CpG methylation of DDR genes shows highest association with the mes-
enchymal (MES) and receptor tyrosine kinase (RTK) II glioblastoma subgroup. MES tumors have lower
tumor purity compared to RTK I and II subgroup tumors. CpG hypomethylation of DDR genes TP73 and
PRPF19 correlated with worse patient survival in particular in MGMT promoter unmethylated tumors.
TERT promoter mutation is most frequent in RTK I and II subtypes and associated with worse survival.
Primary glioma cells show methylation patterns that resemble RTK I and II glioblastoma and long term
established glioma cell lines do not match with glioblastoma subtypes. Silencing of selected resistance
genes PRPF19 and TERT increase sensitivity to temozolomide in vitro. CONCLUSION: Hypomethyla-
tion of DDR genes and TERT promoter mutations is associated with worse tumor prognosis, dependent
on the methylation cluster and MGMT promoter methylation status in IDH wild-type glioblastoma.
DOI: https://doi.org/10.1002/cam4.3447
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Supplementary Figures 
Suppl. Figure S1 
 
 
Suppl. Figure S1: Workflow of the project. 
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Suppl. Figure S2 
 
 
Suppl. Figure S2: TERT expression according to TERT mutation status. Figure shows TERT 
expression measured by RNA sequencing in the subset of the Heidelberg cohort with available RNA  
expression and DNA sequencing data (n = 37).  
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Suppl. Figure S3 
 
 
Suppl. Figure S3: Hierarchical clustering of DDR CpG methylation. Hierarchical clustering of 
DDR CpG methylation shown for the all samples of the three study cohorts combined (NOA-08: n = 
104, EORTC26101: n = 297, Heidelberg cohort: n = 298). The “cg” numbers behind each gene 
correspond to the CpGs in the methylation array.  
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Suppl. Figure S4 
 
 
Suppl. Figure S4: Mean methylation in glioma subgroups and CpG correlation with tumor 
purity. (A) Mean CpG methylation according to methylation classifier assignment. (B) Mean 
methylation of functional DDR CpGs according to classifier assignment. (C-F) Correlation blots 
between selected functional DDR CpG methylation and tumor purity. 
*a full list of classifier abbreviations can be found in the supporting information. 
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Suppl. Figure S5 
 
 
Suppl. Figure S5: Association of glioma subgroups with survival and chromosome 7 alterations. 
(A) Survival curves of patients from the EORTC-26101 study according to methylation classifier 
assignment. (B) MGMT copy number variation according to MGMT promoter methylation and 
methylation classifier assignment. (C) Chromosome 7 gain and (D) EGFR amplification according to 
methylation classifier assignment.  
*a full list of classifier abbreviations can be found in the supporting information. 
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Suppl. Figure S6: Copy number variations of glioma cell lines and primary cultures. (A) 
Heatmap of copy number alterations of 26 important glioma genes of glioma cell lines (n = 4) and 
primary cell cultures (n = 9) determined with methylation EPIC array. (B) Example of a copy number 
profile of the glioma cell line LN308.  
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Suppl. Figure S7 
 
 
Suppl. Figure S7: Knockdown validation with Quantitative real-time PCR (qRT-PCR). (A-C) 
RNA expression measured with qRT-PCR of PRPF19 and TERT in glioma cell lines and primary 
glioma cells transfected with a vector control and two different knockdown constructs per gene 
(shPRPF19_1, shPRPF19_2, shTERT_1 and shTERT_2).  
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Suppl. Figure S8: Tumor cell response to radiotherapy according to PRPF19 and TERT 
knockdown. (A, C, E) Percentage of tumors cells in the G2 phase in cell cycle analysis for vector 
control and two knockdown constructs treated with 2 Gy radiation or control treatment. (B, D, F) 
Clonogenicity of tumor cells transfected with vector control and two knockdown constructs and 
treated with 2 Gy of radiation or control treatment. All panels in this figure represent the mean value 
and SD of three independent experiments.  
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Supplementary Tables 
Suppl. Table S1 
Suppl. Table S1: List of functional CpGs in high grade IDH wildtype glioma 
GpG# Gene Correlation (r-value) Adjusted p-value 
cg17945153 CCND3 -0.532 0.0303 
cg00554702 CHEK1 -0.507 0.0428 
cg13110239 CSNK1E -0.533 0.0303 
cg04728789 CSNK1E -0.514 0.0394 
cg26825849 CUL4A -0.497 0.0494 
cg16121177 EXO1 -0.514 0.0394 
cg04706276 EXO1 -0.500 0.0468 
cg11330941 GEN1 -0.504 0.0458 
cg12434587 MGMT -0.663 0.0008 
cg14194875 MGMT -0.633 0.0024 
cg26990835 MVP -0.512 0.0396 
cg12554573 PARP3 -0.547 0.0262 
cg20765408 PARP4 -0.500 0.0468 
cg12290764 POLE4 -0.539 0.0285 
cg20919922 POLE4 -0.603 0.0057 
cg02058002 POLE4 -0.548 0.0260 
cg02307033 POLE4 -0.561 0.0207 
cg26528128 POLR2E -0.542 0.0278 
cg00778920 PRPF19 -0.538 0.0285 
cg19739774 RPA3 -0.511 0.0396 
cg14289863 SMC5 -0.620 0.0034 
cg13943358 TP73 -0.536 0.0287 
cg23163013 TP73 -0.619 0.0034 
cg03050669 TP73 -0.542 0.0278 
cg06830875 TP73 -0.500 0.0468 
cg18597188 XRCC3 -0.537 0.0285 
cg23193616 XRCC3 -0.526 0.0343 
cg25999604 XRCC3 -0.503 0.0468 
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Suppl. Table S2 
Suppl. Table S2: Molecular characteristics of glioma cell lines and primary cultures 
Name Type Classifier MGMT TERT mut CNV 
A172 Cell line Plexus tumor M C228T Gain of chr 19q, loss of chr 
4q, 6, 8, 11q, 14, 18q, X, 
CDKN2A/B del 
BG5 Primary culture GB RTK I M C228T Gain of chr 7, loss of chr 
10, CDKN2A/B del 
L2 Primary culture GB RTK II M C228T Gain of Chr 7, loss of chr 1q, 
13q 
LN229 Cell line Plexus tumor M C228T Gain of chr 7, 17q, 20, 21 loss 
of chr 6q, 11, CDKN2A/B del  
LN308 Cell line Plexus tumor M C228T Gain of chr 5p, 7p, 20q, 
CDK4 amp 
P3XX Primary culture GB RTK II M C250T Gain of chr 7, 10p, 19, 20, loss 
of chr 4, 9, 19q, X, 
CDKN2A/B del 
S24 Primary culture GB RTK I M C250T Gain of chr 20, loss of chr 
6, 8 and 10, CDKN2A/B 
del 
T1 Primary culture GB RTK I M C228T Gain of chr 7, loss of chr 
10, CDKN2A/B del 
T325 Primary culture No match U C228T Gain of chr 7, loss of chr 
4q, 5q, 6, 8, 10 and 11, 
CDKN2A/B del 
U87116  Cell line Plexus tumor M C228T Gain of chr 7q, 13q, 20q, loss 
of chr 4q, 6p, 9p, 11p, 12p, 
13p, 14p, CDKN2A/B del  
T269 Primary culture GB RTK II M C228T Gain of chr 1, 3, 5, 7, 9, 12-15, 
18-20, 22, CDKN2A/B del 
 
CNV: copy number variation, M: promoter methylated, U: promoter unmethylated, C225T, C250T: 
















The human glioblastoma cell lines U87MG, A172,  LN308 (ATCC; Manassas, USA) and LN229 (N. 
de Tribolet, Lausanne, Switzerland), were kept in complete medium composed of Dulbecco‘s 
modified Eagle Medium (DMEM, High glucose, 4.5 g/l, Sigma-Aldrich, St. Louis, USA) 
supplemented with 10% FBS and 1% penicillin/streptomycin (Sigma-Aldrich). The primary 
glioblastoma cell cultures (glioma initiating cell cultures, GICs) S24, T1, T269 and T325 were 
established from freshly dissected glioblastoma tissue from adult patient after informed consent1. 
Primary glioma cell cultures P3XX and BG5 were kindly provided by H. Miletic, K. G. Jebsen Brain 
Tumour Research Centre, University of Bergen. Primary glioma cell culture L2 was kindly provided 
by F. Siebzehnrubl, European Cancer Stem Cell Research Institute, Cardiff University. Primary 
glioma cell culture E2 was kindly provided by C. Watts, John van Geest Centre for Brain Repair, 
University of Cambridge. Primary glioma cell lines were cultured in neurosphere medium 
(DMEM/F12 medium (Life Technologies, Carlsbad, USA) enriched with B27 supplement, heparin (5 




Temozolomide (Merck, Darmstadt, Germany, catalogue number: T2577 [Sigma-Aldrich]) was 
dissolved in DMSO. Cells were treated after seeded with temozolomide or respective DMSO control. 
As the primary S24 cell cultures were dissected from recurrent glioblastoma, higher doses of 
temozolomide were necessary to obtain reliable effects of temozolomide treatment. In addition, for 
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Generation of lentiviral shRNA knockdown cells  
Knockdown of PRPF19 and TERT gene expression was performed using commercial shERWOOD 
ultramiR lentiviral small hairpin RNAs (shRNA) with pZIP-SFFV-turboRFP-Puro as vector. Overall, 
three different shRNA constructs were tested and the two most effective constructs were used for 
further experiments (for PRPF19: ULTRA-3272605, ULTRA-3272606, ULTRA-3272601, for TERT: 
ULTRA-3380692, ULTRA-3380693, ULTRA-3380694, transOMIC technologies inc., Huntsville, 
USA). A non-targeting RFP tagged shRNA lentiviral construct was used as vector control. Cells were 
selected after transduction by FACS sorting (FACS Canto II, BD) of RFP positive cells and further 
kept under selection with puromycin for culturing conditions.  
 
TERT promoter mutation analysis 
TERT promoter mutation analysis was performed as described before2. DNA was extracted from FFPE 
material. Areas with highest available tumor content were chosen. Extraction was carried out using the 
automated Maxwell system (Promega, Madison, WI, USA). For polymerase chain reaction (PCR), 
20 ng of DNA and KOD Hot Start Master Mix (Merck, Darmstadt, Germany) were employed. Briefly, 
PCR was performed in a total reaction volume of 20 μL and was started with an initial polymerase 
activation step at 95°C for 2 minutes, followed by 35 cycles beginning with denaturation at 95°C for 
20 s, annealing for 45 s at 62°C  temperatures, and extension at 70°C for 10 s, followed by a final 
extension at 70°C for 20 minutes with subsequent cooling to room temperature. The amplification 
product (2 μL) was submitted to bidirectional sequencing using the BigDye Terminator v3.1 
Sequencing Kit (Applied Biosystems, Foster City, CA, USA). Mutations were identified by visual 
analysis of the sequence chromatograms using Sequence Pilot version 3.1 software (JSI‐Medisys, 
Kippenheim, Germany). Primers used for detecting TERT promoter mutations are indicated below. 
Forward (5´-3´): CAGCGCTGCCTGAAACTC, reverse (5´-3´): GTCCTGCCCCTTCACCTT. 
 
 
 Kessler et al. 14 
  
Quantitative real-time PCR (qRT-PCR) 
Total RNA was extracted using a RNA purification system (Qiagen, Hilden, Germany) and cDNA was 
synthesized using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Carlsbad, 
USA). qRT-PCR was performed according to standard protocols in an ABI 7000 thermal cycler using 
primaQUANT qPCR-CYBR-Green Mastermix (Steinbrenner, Wiesenbach, Germany). Standard 
curves were generated for each gene and the amplification was 90–100% efficient. Relative 
quantification of gene expression was determined by comparison of threshold values. All results were 
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  
Primer Sequences:  
qRT-PCR forward (5´- 3´) reverse (5´- 3´) 
human GAPDH CTCTCTGCTCCTCCTGTTCGAC TGAGCGATGTGGCTCGGCT 
human TERT TGTGCACCAACATCTACAAG GCGTTCTTGGCTTTCAGGA 
human PRPF19 ATGTCCCTAATCTGCTCCATCT GAGCCGCCGCTCATAAACA 
 
Clonogenicity assay 
Clonogenic capacity (“clonogenicity”) of glioblastoma cells was analyzed by limiting dilution assay 
(LDA). For that, cells were seeded in 96-well microplates with 300, 50, 8.3 and 1.4 cells in 0.2 ml of 
culture medium per well. Cells were treated after seeding with temozolomide or respective DMSO 
amounts as indicated in the figures, or irradiated with 2 or 4 Gray radiotherapy. After three weeks, 
plates were analyzed for wells showing clones and clonal frequency was calculated using extreme 
limiting dilution (ELDA) software 3.  
 
Cell cycle assay 
For cell cycle, analysis 150,000 cells (LN308) or 300.000 cells (S24) were seeded in 6-well plates and 
treated with the indicated concentrations of temozolomide or DMSO. For assays with radiotherapy, 
cells were irradiated with 2 or 4 Gray. After 72h cells were separated into single cells, incubated in 
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70% ethanol for 1h and stained with 40 µg/ml propidium iodide enriched with 20 µg/ml RNAse for 
30min. FACS analysis was performed using a BD-FACS Canto II flow cytometer. Final data were 
processed with FloJo flow cytometry analysis software (Treestar).  
 
Dimensionality reduction, clustering and correlation network analysis 
Principle component analysis (PCA) is a common method for linear dimensionality reduction that can 
visualize high dimensional data in a two-dimensional diagram using principle components4.  We 
implanted PCA in R with the function “prcomp”, and visualization was done with the package 
“ggplot2” (version 3.2.1). Unsupervised clustering was performed using the package 
“ConsensusClusterPlus” (version 1.48.0) in R.  
A weighted protein correlation network analysis (WPCNA) can identify clusters of methylation sites 
that show high intensity correlation and therefore similar concurrent regulation5. Subsequent 
association with clinical variables identifies correlations between CpG clusters and variables. We 
implemented the WGCNA with the R package “WGCNA” (version 1.68) with minor adaptations for 
the use in methylation analysis. The full methylation dataset with 450,000 CpGs per sample was used 
for WGCNA. Soft threshold was automatically picked based on the criterion of approximate scale-free 
topology, and the network type was defined as signed hybrid. Block wise consensus module detection 
was performed on a 200 GB RAM, 28 core cluster using a block size of 40,000. Associations with 
cluster assignments were calculated using the package “globaltest” (version 5.38.0). All R scripts are 
customized implementations of above-mentioned packages, and the source code can be made available 
upon reasonable request. 
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Methylation classifier abbreviations 
Below the abbreviations of methylation classifier groups in this study are listed. The full current list of 
current brain tumor methylation classifier groups can be downloaded from: 
https://www.molecularneuropathology.org/ 
APA: Methylation class anaplastic pilocytic astrocytoma 
CNS NB FOXR2: Methylation class CNS neuroblastoma with FOXR2 activation 
GBM MES: Methylation class glioblastoma, IDH wildtype, subclass mesenchymal 
GBM Midline: Methylation class glioblastoma, IDH wildtype, subclass midline 
GBM MYCN: Methylation class glioblastoma, IDH wildtype, subclass MYCN 
GBM RTK I: Methylation class glioblastoma, IDH wildtype, subclass RTK (receptor tyrosine kinase) 
I 
GBM RTK II: Methylation class glioblastoma, IDH wildtype, subclass RTK II 
H3K27M: Methylation class diffuse midline glioma H3 K27M mutant 
INFLAM: Methylation class control tissue, inflammatory tumor microenvironment 
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LGG DNT: Methylation class low grade glioma, dysembryoplastic neuroepithelial tumor 
LGG GG: Methylation class low grade glioma, ganglioglioma 
REACT: Methylation class control tissue, reactive tumor microenvironment 
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